CoChat

Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis

Open access
Shi, Jinghua, Liu, Baoli, Wang, Hongmei, Zhang, Tie, Yang, Libo · 2019 · International Journal of Gynecological Cancer

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Background Some clinical and basic research studies have indicated that exposure to metformin might have protective effects against ovarian cancer. However, results from epidemiologic studies have been inconsistent. We performed a meta-analysis to evaluate the effect of metformin use on the risk of ovarian cancer occurrence and mortality.Methods Multiple databases were searched to identify studies on the association between use of metformin and risk of ovarian cancer or prognosis, up to August 2018. Relevant information for analysis was extracted. A random-effects model was used to calculate the pooled risk estimate.Results Thirteen articles were included, of which six articles focused on ovarian cancer incidence and the others focused on prognosis. The pooled OR for ovarian cancer occurrence and mortality comparing metformin use with non-use or use of other hypoglycemic drugs was 0.76 (95% CI 0.62 to 0.93, p = 0.008) and 0.55 (95% CI 0.36 to 0.84, p = 0.006), respectively. Moderate to substantial heterogeneity was observed across included studies.Conclusions Our findings demonstrate that use of metformin was significantly associated with a lower incidence and a better prognosis of ovarian cancer in patients with diabetes. Well-designed interventional studies are warranted to confirm our findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/ijgc-2018-000060

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 34 references

Research works printed but not linked: 1

  1. Li, 2016, The effects of metformin on ovarian cancer: an updated systematic review and meta-analysis, Int J Clin Exp Med, 9, 17559

Cited by

See all 44

Metadata

Authors
Shi, J., Liu, B., Wang, H., Zhang, T., & Yang, L.
Affiliations
Taian City Central Hospital (CN)
Corresponding author
Yang, Libo
Venue
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Published
2019-01
Volume
29
Issue
1
Pages
140-146
ISSN
1048-891X (ISSN-L)
OpenAlex
W2909934544
Cited by
44
References
34
Citations by year
2026: 5 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 8 · 2021: 9 · 2020: 7 · 2019: 5
FWCI
0.64
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Gynecological Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
metformin, ovarian cancer, cancer incidence, cancer mortality, prognosis, diabetes mellitus, antidiabetic drugs, chemoprevention, drug repurposing
MeSH terms
Female, Humans, Hypoglycemic Agents, Metformin, Ovarian Neoplasms, Prognosis, Incidence, Survival Rate, Databases, Factual

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/ijgc-2018-000060
The paper
Shi, J., Liu, B., Wang, H., Zhang, T., & Yang, L. (2019). Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis. International Journal of Gynecological Cancer. https://doi.org/10.1136/ijgc-2018-000060

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.